Key Points {#FPar1856}
==========

The recommended dosage for the Phase II study was 350 mg/m^2^/day in combination with 800 mg of sorafenib daily.The disease control rate was 75% in this Phase I study.Combination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential of an option for advanced HCC.

Introduction {#Sec1}
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related death in the world \[[@CR1]--[@CR3]\]. The prognosis of HCC can be improved by early detection and effective treatment, including resection, liver transplantation, transcatheter arterial chemoembolization (TACE), and radiofrequency ablation (RFA). However, HCC patients with portal vein tumor thrombosis (PVTT) or with extrahepatic metastasis have an extremely poor prognosis \[[@CR4]--[@CR6]\]. According to the consensus-based treatment algorithm for HCC proposed by the Japan Society of Hepatology (JSH), treatment should be performed as if extrahepatic spread is negative or extrahepatic spread is not regarded as a prognostic factor \[[@CR7]\]. Systemic chemotherapy is sometimes performed when liver function is preserved despite the absence of evidence of survival benefit in all stages of HCC. Systemic chemotherapies with various cytotoxic agents for advanced HCC patients have been tested; the response rates in mono- or combination treatment varied and were unsatisfactory. Most phase III studies failed to demonstrate an improvement in overall survival (OS) \[[@CR8], [@CR9]\]. Only a few studies showed improvement in OS in patients with advanced HCC; meanwhile the outcome of liver cancer treatment was different between Eastern and Western patients \[[@CR10]--[@CR13]\]. Currently, there is no standard systemic chemotherapy with cytotoxic agents for advanced HCC patients. However, combination treatment with cytotoxic agents plus molecular targeted agents has the potential for tremendous impact on advanced HCC. The pyrimidine antimetabolite 5-fluorouracil (5-FU) was the first reported chemotherapeutic agent tested in the treatment of HCC, and it has been used with various treatment schedules, dosages, and durations \[[@CR8], [@CR14], [@CR15]\]. It has been reported that, when used in combination therapy with 5-FU, several drugs that are modulators that increase 5-FU activity improved the response rate or OS in advanced HCC patients in small trials \[[@CR16]--[@CR18]\].

Sorafenib is the first molecular targeted drug approved for the treatment of advanced HCC and is a potent small molecule inhibitor of multiple kinases, including the serine-threonine kinase Raf-1, the tyrosine kinases, vascular endothelial growth factor receptor (VEGFR), and the platelet-derived growth factor receptor-β with anti-proliferative and anti-angiogenic activities. Preclinical studies have shown that sorafenib controls tumor proliferation through inhibition of the MAP kinase cascade and tumor angiogenesis through inhibition of VEGFR \[[@CR19]\]. The phase III Sorafenib HCC Assessment Randomized Protocol (SHARP) trial demonstrated prolonged overall and progression-free survival in patients with unresectable HCC who were treated with sorafenib, compared with those who received placebo \[[@CR20]\]. A randomized, double-blind, placebo-controlled study in the Asia Pacific region demonstrated the efficacy and safety of sorafenib in advanced HCC, similar to the SHARP study \[[@CR21]\]. According to the Barcelona Clinic Liver Cancer (BCLC) staging classification, advanced stage (stage C) patients who have vascular invasion or extrahepatic spread but conserved liver function are candidates for systemic therapy with sorafenib \[[@CR22]\]. According to the modified form of the original version of the consensus-based treatment algorithm for HCC proposed by the JSH in 2014, sorafenib is the standard of care for patients with an extrahepatic lesion or with TACE-refractory or TACE-failure disease in Japan \[[@CR7]\]. However, the antitumor effects are insufficient for controlling the large and numerous nodules of HCC and for preventing a high rate of tumor recurrence after treatment \[[@CR23]--[@CR25]\]. A series of clinical studies on the molecular targeted drugs for HCC such as brivanib \[[@CR26], [@CR27]\], sunitinib \[[@CR28]\], linifanib \[[@CR29]\], ramucirumab \[[@CR30]\], everolimus \[[@CR31]\], and erlotinib \[[@CR32]\] has been conducted. No molecular targeted drugs other than sorafenib significantly improve OS in patients with advanced HCC; so far sorafenib is still standard treatment for advanced HCC.

It was previously reported that the serum VEGF level correlated with tumor progression and poor prognosis \[[@CR33], [@CR34]\]. In addition to its direct anti-angiogenic effects, these VEGFR-targeted agents may enhance chemotherapy by normalizing tumor vasculature and decreasing the elevated interstitial pressure in tumors \[[@CR35]\]. These reports suggest that combination therapy with sorafenib and cytotoxic agents such as 5-FU has the potential to have additive anticancer activity. Petrini et al. reported a phase II study of combination therapy with sorafenib and 5-FU \[[@CR36]\]. Their treatment schedule was 800 mg of sorafenib daily and continuous infusion of 5-FU (200 mg/m^2^/day) from day 1 to 14 (21-day cycles), although high-dose 5-FU was used with manageable side effects in previous reports \[[@CR16]--[@CR18]\]. Their results showed that the median time to progression (TTP) was 8 months \[95% confidence interval (CI) 5.7--10.4\], and median OS was 13.7 months (95% CI 9.5--17.9). Therefore, combination therapy with sorafenib and high-dose 5-FU must be tested as a potential treatment option for advanced HCC.

The purpose of this phase I study was to evaluate the safety and tolerability of combination therapy with sorafenib and dose escalation of continuous infusion of 5-FU at three dosage levels (250, 350, and 450 mg/m^2^/day), as well as tumor response in patients with advanced HCC.

Materials and Methods {#Sec2}
=====================

Study Design {#Sec3}
------------

The study was a non-randomized, uncontrolled, non-blinded, phase I study to investigate the safety and tolerability of combination treatment with sorafenib and 5-FU in patients with advanced HCC. The primary endpoint was to determine the maximum tolerated dose (MTD) of 5-FU in combination therapy with sorafenib and to define the recommended dosage (RD) for phase II. Secondary endpoints included toxicity and the response rate. Enrollment began in September 2010, and the study closed in September 2011. The study protocol was approved by the Institutional Review Board of Hokkaido University and the ethics committee of Hokkaido University Hospital (IRB010-0099). Written, informed consent to participate in this study was obtained from each patient. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its comparable ethical standards. This study was registered at the UMIN Clinical Trials Registry as UMIN000004313.

Eligibility Criteria {#Sec4}
--------------------

The eligibility criteria for this study were as follows: (1) patients with advanced HCC confirmed histologically or clinically based on the American Association for the Study of Liver Diseases guidelines \[[@CR37]\]; (2) unresectable and incurable with RFA or TACE; (3) age ≥20 years; (4) at least one measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) scans (not including necrotic lesions caused by prior treatment); (5) other prior treatments without systemic chemotherapy permitted if such treatment performed at least 28 days before registration; (6) cirrhotic status of Child--Pugh A; (7) Eastern Cooperative Oncology Group performance status of 0 or 1; (8) hematological findings (neutrophil count of ≥1500 cells/mm^3^, platelet count of ≥50,000 cells/mm^3^, and hemoglobin of ≥10.0 g/dL), renal function (serum creatinine concentration of ≤1.5 × ULN), and hepatic function (total bilirubin level of ≤2.0 mg/dL, aspartate and alanine transaminase levels of ≤5.0 × ULN); and (9) written, informed consent from the patient. Patients who previously received systemic anticancer therapy or molecular target therapy including sorafenib were excluded from this study. Other exclusion criteria were (1) uncontrollable ascites; (2) varices in the esophagus or stomach with a high risk of bleeding; (3) medical history of hepatic coma; (4) clinically evident congestive heart failure, serious cardiac arrhythmias, active or symptomatic coronary artery disease or ischemia; (5) primary and metastatic brain tumors; (6) history of organ allograft; (7) prior malignancy; (8) treatment with biologic-response modifiers or CYP3A4 inhibitors; or (9) medical/psychological/social problems that might affect study participation or evaluations.

Treatment Protocol {#Sec5}
------------------

This study used a conventional 3 + 3 dose-escalation design. All patients received sorafenib 800 mg daily and three planned dosage levels of 5-FU (250, 350, and 450 mg/m^2^/day) for 20 days (day 1--5, 8--12, 15--19, and 22--26) by intravenous infusion from an implantable infusion port with an infusion device in 1 month (as one cycle) (Fig. [1](#Fig1){ref-type="fig"}). If none of the first three patients had dose-limiting toxicity (DLT), the dose was increased to the next dose level. If one or two of the first three patients had DLT, three additional patients were assigned to the same dose level; if only one or two of the six patients had DLT, the dose was increased to the next dose level; if all of the three patients or three or more of the six patients had DLT, the dose was defined as the MTD; the RD was defined as the level one step below the MTD. DLT was defined as the occurrence of any of the following toxicities: (1) hematologic toxicity of grade 4; (2) febrile (≥38.5 °C) neutropenia of grade 3; (3) thrombocytopenia of grade 3 that needed blood infusion for recovery; or (4) non-hematologic event of grade 3.Fig. 1A 3 + 3 dose-escalation study design. Continuous sorafenib 800 mg/day and 3 planned dose levels of 5-FU (250, 350, and 450 mg/m^2^/day) for 20 days (day 1--5, 8--12, 15--19, and 22--26) by intravenous infusion in 1 month as one cycle. *5-FU* 5-fluorouracil

Safety Monitoring and Efficacy of Treatment {#Sec6}
-------------------------------------------

Safety measurements included monitoring for adverse events (AEs) using the National Cancer Institute Common Toxicity Criteria, version 4.0 (NCI CTCAE v4.0) in one cycle. AEs from the use of combination therapy were monitored until recovery or remission. If toxicities associated with sorafenib occurred, the dose of sorafenib was reduced according to the drug information. Tumor response measurements, based on the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) \[[@CR38]\], were performed at baseline (within 21 days before initiation of treatment) and after one cycle (within 14 days of cessation or completion of treatment). The number and percentage of patients achieving complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), and the disease control rate (DCR,%) (CR + PR + SD/CR + PR + SD + PD) were analyzed. For patients with SD or an objective response, follow-up assessments for survival were performed every 4 weeks until PD and/or death. After one cycle of combination therapy, sorafenib monotherapy was administered in consultation with the doctor in charge of the patient.

Patients' Characteristics {#Sec7}
-------------------------

A total of 12 patients (all men; median age 65 years, age range 49--75 years) were enrolled in the study from September 2010 to September 2011. The performance status of all patients was 0. The etiologies of HCC were HBV in four (33.3%), HCV in two (16.7%), and others in six (50%). The median maximum tumor size was 6.8 cm (range 1.0--9.6 cm), and 11 patients (91.7%) were Union for International Cancer Control (UICC) TNM stage IV-B. The number of patients was three (25%) in cohort 1, three (25%) in cohort 2, and six (50%) in cohort 3 according to the 3 + 3 design. The patients' characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Patients' baseline characteristicsCohort 1Cohort 2Cohort 3Total (range or %)5-FU dose (mg/m^2^)250350450Number of patients33612Age or median age (range) (years)64, 74, 6574, 49, 5565 (54--75)65 (49--75)Sex: male, female3, 03, 06, 012, 0 (100, 0%)ECOG status: 0, 13, 03, 06, 012, 0 (100, 0%)Etiology: HBV, HCV, others1, 0, 22, 0, 11, 2, 34, 2, 6 (33.3, 16.7, 50%)Radiological features (CT) Median tumor diameter (cm)5 (1.3--7.3)7.9 (2.5--9.6)6.8 (1.0--9.1)6.8 (1.0--9.6) Portal invasion001 (segmental)1 (8.3%)UICC stage I--II0000 III0011 (8.3%) IV-A0000 IV-B33511 (91.7%)Location of metastases Lung2215 (41.7%) Lymph node1236 (50%) Bone1113 (25%) Others1113 (25%)Median AFP (ng/mL)4.2 (3.0--5931.2)191.8 (4.0--571.0)20.8 (5.2--126.0)20.8 (3.0--5931.2)Median PIVKA-II (mAU/mL)2130 (763--23,199)11500 (19--42,522)2480 (23--110,648)2130 (19--110,648)Prior treatments None1135 (41.7%) Surgery1023 (25%) Ablation therapy0000 TACE1203 (25%) HAIC0011 (8.3%)*5-FU* 5-fluorouracil, *AFP* alpha-fetoprotein, *CT* computed tomography, *ECOG* Eastern Cooperative Oncology Group, *HAIC* hepatic arterial infusion chemotherapy, *HBV*hepatitis B virus*, HCV*hepatitis C virus*,* *PIVKA-II* protein induced by vitamin K absence or antagonist II, *TACE* transcatheter arterial chemoembolization, *TNM* tumor, node, metastasis, *UICC* Union for International Cancer Control

Results {#Sec8}
=======

Evaluation of DLT and MTD {#Sec9}
-------------------------

The schedule of administration is shown in Fig. [1](#Fig1){ref-type="fig"}. There were three to six patients in each cohort. The first three patients started at a dose of 250 mg/m^2^ of 5-FU and sorafenib 800 mg daily (cohort 1); there were no DLTs observed during follow-up. The next three patients were treated with a dose of 350 mg/m^2^ of 5-FU and sorafenib 800 mg daily (cohort 2); there were no DLTs observed during follow-up. The next three patients were treated with a dose of 450 mg/m^2^ of 5-FU and sorafenib 800 mg daily (cohort 3); there were two DLTs observed, and an additional three patients were treated with the same dose. Ultimately, two of six patients in cohort 3 developed DLTs. Given these results, the MTD of 5-FU in combination therapy with sorafenib was 450 mg/m^2^, and 350 mg/m^2^ was defined as the RD for phase II study.

Safety {#Sec10}
------

Table [2](#Tab2){ref-type="table"} shows the frequency of AEs. The non-hematologic AEs of any grade were fatigue (50%), appetite loss (50%), anorexia (56%), vomiting (8.3%), stomatitis (33.3%), hand-foot skin reaction (HFSR) (58.3%), skin rash (8.3%), hypoxia (8.3%), aspartate aminotransferase (AST) abnormality (25%), alkaline phosphatase (ALP) abnormality (8.3%), bilirubin abnormality (16.7%), and hypoalbuminemia (8.3%). The hematologic abnormalities of any grade were neutropenia (25%) and thrombocytopenia (41.7%). Febrile neutropenia and anemia were not observed. The observed grade 3 non-hematologic AEs were stomatitis (8.3%) and HFSR (16.7%). Only thrombocytopenia (8.3%) was seen as a grade 3 hematologic AE. There were two DLTs observed in cohort 3. One patient had grade 3 thrombocytopenia that needed blood infusion to recover, and the other patient had grade 3 stomatitis and grade 3 HFSR. Two patients needed dose reduction of sorafenib in cohort 2. Their adherence rates to sorafenib were 75 and 87.5%, respectively. Four patients needed dose reduction of sorafenib in cohort 3; three of them required the discontinuation of sorafenib for 1--2 week. Their adherence rates to sorafenib were 62.5%, 62.5, 50, and 50%, respectively.Table 2Adverse eventsCohort 1 (*n* = 3)Cohort 2 (*n* = 3)Cohort 3 (*n* = 6)G1G2G3G4G1G2G3G4G1G2G3G4Hematologic Febrile neutropenia------------------------ Neutropenia1--------1------1---- Anemia------------------------ Thrombocytopenia--1----1--1--2------Non-hematologic Fatigue3---------------------- Nausea------------------------ Appetite loss--1------------1------ Vomiting------------------------ Diarrhea------------------------ Stomatitis--------1--------21-- Hand--foot skin reaction--1------2------22-- Skin rash--------1--------1---- Hypertension------------------------ Hypoxia--2-------------------- Hoarseness----------------1------ AST abnormality1------2------−1------ ALT abnormality------------------------ ALP abnormality1---------------------- Bilirubin abnormality--------1------1------ Hypoalbuminemia--------1-------------- Epistaxis------------------1----Data are numbers*ALT* alanine aminotransferase, *ALP* alkaline phosphatase, *AST* aspartate aminotransferase, *G* grade

Efficacy {#Sec11}
--------

Ten patients were evaluated for tumor response after one cycle of treatment by mRECIST. Two DLT patients were evaluated at the time of discontinuation of treatment. Table [3](#Tab3){ref-type="table"} shows the summary of efficacy. Nine patients achieved SD (75%), and three patients achieved PD (25%). The DCR was 75%. In detail, two patients in cohort 1 and one DLT patient in cohort 3 achieved PD.Table 3EfficacyNumber of patientsResponse *n* (%)CRPRSDPDCohort 13001 (33.3)2 (66.7)Cohort 23003 (100)0Cohort 36005 (58.3)1 (16.7)*CR* complete response, *PD* progressive disease, *PR* partial response, *SD* stable disease

Case {#Sec12}
----

A 74-year-old man was diagnosed with moderately differentiated HCC at the time of hepatic resection 1 year before being enrolled in this study. Multiple metastases of HCC were observed on chest CT affecting both lungs before treatment (Fig. [2](#Fig2){ref-type="fig"}a). After combination therapy with sorafenib and 5-FU, the multiple lung metastases of HCC progressed, and a new lesion was detected at the right lobe of the lung (Fig. [2](#Fig2){ref-type="fig"}b). This case was evaluated as PD by mRECIST in this study. Six months after the beginning of treatment, multiple lung metastases of HCC showed PR, and the newly detected lesion disappeared (Fig. [2](#Fig2){ref-type="fig"}c).Fig. 2A 74-year-old man diagnosed with moderately differentiated HCC. **a** Multiple lung metastases of HCC are observed before combination treatment on chest CT. **b** After one cycle, multiple metastases of HCC are enlarged and diagnosed as progressive disease on chest CT. **c** Six months after treatment, multiple metastases of HCC show partial response on chest CT. *CT* computed tomography, *HCC* hepatocellular carcinoma

Discussion {#Sec13}
==========

The aim of this study was to evaluate the safety and tolerability of combination therapy with sorafenib and cytotoxic agents. Furthermore, the aim was also to determine the RD of 5-FU for a phase II study. It has been reported that agents that inhibit VEGFR might enhance cytotoxic agents by normalizing tumor vasculature and decreasing the elevated interstitial pressure in tumors \[[@CR35]\]. These effects were considered of value for HCC. In this study, intravenous infusion of 5-FU was combined with sorafenib. 5-FU monotherapy has been shown to be ineffective for advanced HCC. However, several drugs that are modulators that might increase 5-FU activity, when used in combination therapy with 5-FU, improved response rates or OS in advanced HCC patients in small phase II trials \[[@CR16]--[@CR18]\]. The methods of 5-FU administration were tested by various treatment schedules, dosages, and durations in the treatment of HCC \[[@CR8], [@CR14], [@CR15]\], and intravenous infusion of 5-FU used in the present study was found to be safe and tolerable. For that reason, we began to investigate the efficacy of combination therapy with sorafenib and cytotoxic agents using intravenous infusion of 5-FU. Several combination therapies with sorafenib and cytotoxic agents for advanced HCC have been reported. The combination therapy with sorafenib and doxorubicin was found to have efficacy and tolerability for advanced HCC patients in a double-blind, phase II, multinational study \[[@CR39]\]. Unfortunately, the treatment with sorafenib and doxorubicin did not improve OS compared with sorafenib alone in a phase III study \[[@CR40]\]. Petrini et al. reported a phase II study of combination therapy with sorafenib and intravenous infusion of 5-FU \[[@CR36]\]. Their treatment schedule was sorafenib 800 mg/day and continuous infusion of 5-FU (200 mg/m^2^/day) for days 1--14 (21-day cycles). The median TTP was 8 (95% CI 5.7--10.4) months, and median OS was 13.7 (95% CI 9.5--17.9) months. They concluded that combination therapy with sorafenib and intravenous infusion of 5-FU was safe and feasible. Moreover, high-dose intravenous infusion of 5-FU was reported to have manageable side effects in previous reports \[[@CR16]--[@CR18]\]. These facts encouraged us to perform combination therapy with sorafenib and high-dose 5-FU infusion for advanced HCC patients. Intravenous infusion of 5-FU (250, 350, or 450 mg/m^2^/day) for 20 days (day 1--5, 8--12, 15--19, and 22--26) in 1 month as one cycle was selected.

In this study, four cases (33.3%) of stomatitis occurred as AEs, and one of them had DLT (8.3%). Stomatitis might occur frequently as a side effect of 5-FU, but this is often not the case as a side effect of sorafenib monotherapy. This is a critical AE for combination therapy and may need careful management in preparation for a phase II study.

The limitation of this study was that all patients were treated by intravenous 5-FU infusion for a long time and required 2 weeks hospitalization for monitoring DLT. In this study, we determined the RD of 5-FU in combination use with sorafenib, and we plan to treat study participants as outpatients in the next phase II study. The other limitation was the evaluation timing for response rate. As shown in the case, evaluation after one cycle might not be adequate for tumor response. With sorafenib monotherapy, a long duration of drug therapy improved TTP or OS, and longer periods of evaluation of tumor response might be needed with this combination therapy.

In conclusion, combination therapy with sorafenib and intravenous infusion of 5-FU for advanced HCC appears to be well-tolerated and may have the potential of therapeutic effects compared with sorafenib monotherapy.
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